European shares fall: Trump threatens ’massive’ tariff increase on China
MeiraGTx Holdings plc (NASDAQ:MGTX) stock achieved a new 52-week high this week, reaching a price level of $7.9, marking an impressive 50.8% surge over the past six months according to InvestingPro data. This milestone reflects a significant recovery and a positive trend for the biotechnology company, which specializes in gene therapy. The company, currently valued at approximately $501 million, maintains a healthy liquidity position with a current ratio of 2.34. Over the past year, MeiraGTx Holdings has seen its stock value increase by 8.64%, indicating a steady climb and growing investor confidence in the company’s prospects and the broader biotech sector. InvestingPro analysis reveals 8 additional key insights about MGTX’s financial health and growth potential. The achievement of this 52-week high serves as a testament to the company’s resilience and potential for growth in a competitive market. Notably, analyst targets range from $11 to $36, suggesting significant upside potential, though investors should note the company’s current unprofitable status with negative EBITDA of $162.8 million in the last twelve months.
In other recent news, MeiraGTx Holdings plc announced a significant strategic collaboration with Hologen AI, which includes a $200 million upfront payment and the creation of a joint venture, Hologen Neuro AI Ltd. This venture will receive an additional $230 million from Hologen to advance the development of AAV-GAD, a treatment for Parkinson’s disease, and other central nervous system therapies. MeiraGTx retains a 30% ownership stake in the joint venture and will manage all clinical development and manufacturing operations. The partnership aims to leverage Hologen’s generative AI technology to enhance clinical development, with Hologen also acquiring a minority interest in MeiraGTx’s manufacturing subsidiary. Piper Sandler maintained its Overweight rating on MeiraGTx, with a price target of $26, highlighting upcoming catalysts such as pivotal data for AAV-hAQP1 in xerostomia and the potential commercialization of botavec by Johnson & Johnson. The firm emphasized these developments as underappreciated opportunities that could drive value for MeiraGTx. The transactions with Hologen are subject to customary closing conditions, with completion expected in the second quarter of 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.